EUVIMEDEUVIMED entdecken
Open Access

Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825

Joshua D Strauss iD, Mark R Gilbert iD, Minesh Mehta, Ang Li, Renke Zhou, Melissa L Bondy, Erik P Sulman, Ying Yuan iD, Yanhong Liu, Elizabeth Vera, Merideth M Wendland, Volker W Stieber und 11 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Joshua D Strauss und 22 weiteren Autor:innen. Beteiligte Einrichtung: Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Glioblastoma, Polymorphism, Single Nucleotide, Brain Neoplasms, Hypertension. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Voices Against Brain Cancer Foundation and Genentech, NINR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is an aggressive form of brain cancer in which treatment is associated with toxicities that can result in therapy discontinuation or death. This analysis investigated clinical and genetic markers of vascular toxicities in GBM patients during active treatment.

Methods

In total, 591 non-Hispanic White GBM patients with clinical data were included in the analysis from NRG RTOG-0825. Genome-wide association studies (GWAS) were performed from genotyped blood samples (N = 367) by occurrence of thrombosis or hypertension (grade ≥ 2). A clinical prediction model was produced for each vascular toxicity. Significant GWAS variants were then added to the clinical model as a single nucleotide polymorphism (SNP)-dose-effect variable to produce the final genetic models.

Results

Thrombosis and hypertension were experienced by 62 (11%) and 59 (10%) patients, respectively. Patients who experienced hypertension displayed improved survival over those without hypertension (median overall survival: 25.72 vs. 15.47 months, p = 0.002). The genetic model of thrombosis included corticosteroid use (odds ratio [OR]: 7.13, p = 0.02), absolute neutrophil count (OR: 1.008, p = 0.19), body surface area (OR: 18.87, p = 0.0008), and SNP-dose effect (3 variants; OR: 3.79, p < 0.0001). The genetic model of hypertension included bevacizumab use (OR: 0.97, p = 0.95) and the SNP-dose effect (6 variants; OR: 4.44, p < 0.0001).

Conclusions

In this study, germline variants were superior in predicting hypertension than clinical variables alone. Additionally, corticosteroid use was a considerable risk factor for thrombosis. Future investigations should confirm the hazard of corticosteroid use on thrombosis and the impact of bevacizumab in other malignancies after accounting for the genetic risk of hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPolymorphism, Single NucleotideBrain NeoplasmsHypertensionThrombosisHumansFemaleMaleMiddle AgedGenome-Wide Association StudyAgedAdultPrognosisSurvival RateFollow-Up StudiesBevacizumabGenetic MarkersBiomarkers, TumorYoung Adult

Stichwörter der Autor:innen

bevacizumabgenome-wide association studyglioblastomahypertensionthrombosis

Substanzen

BevacizumabGenetic MarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
  • Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Pediatrics, Center for Epidemiology and Population Health, Baylor College of Medicine, Houston, Texas, USA.
  • Neuro-Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA.
  • Radiation Oncology, Miami Cancer Institute, Miami, Florida, USA.
  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Joshua D Strauss, Mark R Gilbert, Ying Yuan, Vivian A Guedes, Melissa A Richard, Terri S Armstrong, Michael E Scheurer

Förderung

  • NCI NIH HHS
  • Voices Against Brain Cancer Foundation and Genentech
  • NINR NIH HHS
  • the National Cancer Institute
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Strauss, J. D., Gilbert, M. R., Mehta, M., Li, A., Zhou, R., Bondy, M. L., Sulman, E. P., Yuan, Y., Liu, Y., Vera, E., Wendland, M. M., Stieber, V. W., Puduvalli, V. K., Choi, S., Martinez, N. L., Robins, H. I., Hunter, G. K., Lin, C. F., Guedes, V. A., …, & Scheurer, M. E. (2025). Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae234

Vancouver

Strauss JD, Gilbert MR, Mehta M, Li A, Zhou R, Bondy ML, et al. Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae234

BibTeX
@article{Strauss2025,
  author = {Strauss, Joshua D and Gilbert, Mark R and Mehta, Minesh and Li, Ang and Zhou, Renke and Bondy, Melissa L and Sulman, Erik P and Yuan, Ying and Liu, Yanhong and Vera, Elizabeth and Wendland, Merideth M and Stieber, Volker W and Puduvalli, Vinay K and Choi, Serah and Martinez, Nina L and Robins, H Ian and Hunter, Grant K and Lin, Chi-Fan and Guedes, Vivian A and Richard, Melissa A and Pugh, Stephanie L and Armstrong, Terri S and Scheurer, Michael E},
  title = {Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae234}
}
Kostenlos starten →